Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Epirubicin, Cisplatin, Capecitabine, Panitumumab · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1: ECX + Panitumumab | EXPERIMENTAL | - |
| Arm 2: EXC alone | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Epirubicin, Cisplatin, Capecitabine, Panitumumab | DRUG | Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle; Panitumumab: 9 mg/kg bodyweight, administered IV by an infusion pump through a peripheral line or catheter over 60 min +-15 min on day 1 of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops. |
| Epirubicin, Cisplatin, Capecitabine | DRUG | Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops. |
Inclusion Criteria: * Competent to comprehend, sign, and date an IEC-approved informed consent form, written informed consent. * Of either gender and aged 18 years or more. * Diagnosed with histologically confirmed adenocarcinoma of the stomach or the gastroesophageal junction of Type I/II/III acco...
Epirubicin is an oncology small molecule being studied for stomach neoplasms, breast cancer, and esophagogastric junction adenocarcinoma. It is currently in Phase 3 clinical development. Epirubicin is being evaluated in combination with other agents in clinical trials for these cancer types.
Epirubicin is being developed by Amgen Inc., which trades under the ticker AMGN. The company is conducting clinical trials to evaluate the drug in oncology indications including breast cancer and gastric cancers.
Epirubicin is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in completed Phase 3 trials for early breast cancer and in earlier-phase trials for gastric and esophagogastric junction cancers.
Epirubicin has been studied in several completed trials. NCT00309556 was a Phase 3 randomized neoadjuvant study in early breast cancer. NCT00719550 was a Phase 1 trial combining epirubicin with AMG 102 for gastric or esophagogastric junction cancer. NCT01234324 was a Phase 2 trial of epirubicin with panitumumab in gastric cancer. NCT01690702 was a Phase 3 study in high-risk early breast cancer.
Epirubicin is a small molecule oncology drug. Its specific molecular target is not disclosed in the available clinical trial information. The drug is being studied in combination with other therapies for the treatment of breast cancer and gastric cancers.
No, Epirubicin is not the same as AMG 102. In clinical trial NCT00719550, epirubicin was combined with AMG 102, which is a separate investigational agent. Epirubicin is the chemotherapy drug being evaluated in that trial, while AMG 102 is the experimental combination partner.